J Zhang, D Huang, PE Saw, E Song - Trends in Immunology, 2022 - cell.com
Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most 'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …
J Zhang, D Huang, PE Saw… - Trends in …, 2022 - pubmed.ncbi.nlm.nih.gov
Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most'immune-cold'solid tumors are not responsive. The diversity of immune evasion …
J Zhang, D Huang, PE Saw, E Song - Trends in Immunology, 2022 - europepmc.org
Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most'immune-cold'solid tumors are not responsive. The diversity of immune evasion …
J Zhang, D Huang, PE Saw, E Song - Trends in Immunology, 2022 - Elsevier
Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most 'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …
J Zhang, D Huang, PE Saw, E Song - Trends in Immunology, 2022 - Elsevier
Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most 'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …